Takeda and Pfizer report positive Phase III HD21 trial of ADCETRIS

Takeda and Pfizer have announced a positive Phase III HD21 trial, evaluating ADCETRIS (brentuximab vedotin) in combination with chemotherapy.

The trial has shown superior progression-free survival (PFS) and improved tolerability in patients with newly diagnosed Hodgkin lymphoma.